Advertisement
Clinical Therapeutics
Advanced searchSave search
Research Article| Volume 31, ISSUE 9, P1908-1921, September 2009

Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children

DOI:https://doi.org/10.1016/j.clinthera.2009.09.001
Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children
Previous ArticleRomiplostim in chronic immune thrombocytopenic purpura
Next ArticleA multicenter, randomized, double-blind, placebo- controlled trial of intravenous ibuprofen 400 and 800 mg every 6 hours in the management of postoperative pain
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Background: Bepotastine besilate is a highly selective histamine H1-receptor antagonist with antihistaminic, mast cell stabilizing, and anti-inflammatory activity. Based on a history of clinical effectiveness and tolerability of oral bepotastine besilate in the treatment of allergic symptoms, bepotastine besilate is being tested as a potential ophthalmic medication for allergic conjunctivitis.
      Objective: The aim of this study was to assess the effects of bepotastine besilate ophthalmic solution 1.0% and 1.5% for the treatment of ocular itching and conjunctival hyperemia in a conjunctival allergen challenge (CAC) model in adults and children.
      Methods: This Phase III, single-center, prospective, randomized, double-masked, placebo-controlled, CAC clinical trial enrolled patients ≥10 years of age with a history of allergic conjunctivitis, skin-test reaction, and CAC response. Patients received bepotastine besilate ophthalmic solution 1.0%, bepotastine besilate ophthalmic solution 1.5%, or placebo, 1 drop on each eye on days 14 ± 3 and 28 ± 3. The primary efficacy end points, patient-assessed ocular itching (at 3, 5, and 7 minutes) and investigator-assessed conjunctival hyperemia (at 7, 15, and 20 minutes), were determined after CAC according to standardized 5-point scales (0 = none to 4 = severe). Clinical significance was defined in the protocol as ≥1.0-U between-group difference in mean ocular itching scores at the majority of time points at a study visit and also a ≥0.5-U difference at all time points. Tolerability of the test agent was assessed by visual acuity, slit-lamp biomicroscopy, intraocular pressure, dilated funduscopy, and adverse events.
      Results: A total of 107 patients (male, 54%; age range, 11–73 years; white race/ethnicity, 93%) received investigational product and comprised the intent-to-treat (ITT) population (bepotastine besilate ophthalmic solution 1.0%, 36 patients; bepotastine besilate ophthalmic solution 1.5%, 35; and placebo, 36). All 107 patients received investigational product at visit 3A (day 0) and were included in the ITT population. Of the 107 patients who were enrolled, 103 completed the study without a protocol deviation or violation. The 1.0% and 1.5% solutions were associated with clinically and statistically significant reductions in mean ocular itching scores compared with placebo on the 15-minute onset-of-action and 8-hour duration-of-action CAC tests (reductions, 1.3–1.5 U and 1.0–1.7 U respectively; all, P < 0.001). Statistically significant reductions in conjunctival hyperemia were achieved with both bepotastine besilate concentrations. Overall, 13 patients experienced a treatmentemergent adverse event considered related to the study drug (bepotastine besilate ophthalmic solution 1.0%, 6 patients; bepotastine besilate ophthalmic solution 1.5%, 4; and placebo, 3).
      Conclusions: In this CAC model of allergic conjunctivitis in adults and children, bepotastine besilate ophthalmic solutions 1.0% and 1.5% were associated with clinically and statistically significant reductions in ocular itching, but not conjunctival hyperemia, within 15 minutes that were maintained for at least 8 hours after administration. Both solutions were well tolerated. ClinicalTrials.gov identifier: NCT00424398.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Abelson MB
        • Chapin MJ
        Current and future topical treatments for ocular allergy.
        Comp Ophthalmol Update. 2000; 1: 303-317
        • Abelson MB
        • Smith L
        • Chapin M
        Ocular allergic disease: Mechanisms, disease sub-types, treatment.
        Ocu Surf. 2003; 1: 127-149
        • Canonica GW
        • Ciprandi G
        • Petzold U
        • et al.
        Topical azelastine in perennial allergic conjunctivitis.
        Curr Med Res Opin. 2003; 19: 321-329
        • Berger W
        • Abelson MB
        • Gomes PJ
        • et al.
        Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy.
        Ann Allergy Asthma Immunol. 2005; 95: 361-371
        • Abelson MB
        • Paradis A
        • et al.
        Effects of Vasocon-A in the allergen challenge model of acute allergic conjunctivitis.
        Arch Ophthalmol. 1990; 108: 520-524
        • Verin P
        • Easty DL
        • Secchi A
        • et al.
        Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis.
        Am J Ophthalmol. 2001; 131: 691-698
        • Abelson MB
        • Berdy GJ
        • Mundorf T
        • et al.
        Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: A pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies.
        J Ocul Pharmacol Ther. 2002; 18: 475-488
        • Shulman DG
        Two mast cell stabilizers, pemirolast potassium 0.1% and nedocromil sodium 2%, in the treatment of seasonal allergic conjunctivitis: A comparative study.
        Adv Ther. 2003; 20: 31-40
        • Yaylali V
        • Demirlenk I
        • Tatlipinar S
        • et al.
        Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis.
        Acta Ophthalmol Scand. 2003; 81: 378-382
        • Abelson M
        • Howes J
        • George M
        The conjunctival provocation test model of ocular allergy: Utility for assessment of an ocular corticosteroid, loteprednol etabonate.
        J Ocul Pharmacol Ther. 1998; 14: 533-542
        • Abelson MB
        • Spitalny L
        Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
        Am J Ophthalmol. 1998; 125: 797-804
        • Abelson MB
        • Gomes P
        • Gomes P
        • et al.
        Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.
        Clin Ther. 2004; 26: 35-47
        • Abelson MB
        • Gomes PJ
        • Pasquine T
        • et al.
        Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis.
        Allergy Asthma Proc. 2007; 28: 427-433
        • Simons FE
        Advances in H1-antihistamines.
        N Engl J Med. 2004; 351: 2203-2217
        • Tashiro M
        • Duan X
        • Kato M
        • et al.
        Brain histamine H1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with 11C-doxepin.
        Br J Clin Pharmacol. 2008; 65: 811-821
        • Kato M
        • Nishida A
        • Aga Y
        • et al.
        Pharmacokinetic and pharmacodynamic evaluation of central effect of the novel antiallergic agent bepotastine besilate.
        Arzneimittelforschung. 1997; 47: 1116-1124
        • Yato N
        • Murata T
        • Saito N
        • et al.
        Anti-allergic activity of betotastine besilate (TAU-284), a new antiallergic drug [in Japanese].
        Nippon Yakurigaku Zasshi. 1997; 110: 19-29
        • Sakai A
        • Kikuchi M
        • Yato N
        • et al.
        Inhibitory effect of betotastine besilate on antigen-induced airway eosinophil infiltration and peripheral blood eosinophilia in mice.
        Arzneimittelforschung. 1997; 47: 954-958
        • Ukai K
        • Takeuchi M
        • Masuda S
        • et al.
        Clinical pharmacological study of antiallergic agent TAU-184 (bepotastine besilate)—the effect on counting of eosinophils in nasal discharge, and the patency improvement of nasal cavity [in Japanese].
        J Clin Ther Med. 1997; 13: 1401-1412
        • Ueno M
        • Inagaki N
        • Nagai H
        • Koda A
        Antiallergic action of bepotastine besilate (TAU-284) in animal models: A comparison with ketotifen.
        Pharmacology. 1998; 57: 206-214
        • Honda H
        • Murata K
        • Hamazaki A
        • et al.
        Inhibitory effect on anaphylactic reaction and histamineantagonizing action [in guinea pigs] of betotastine besilate (TAU-284), a novel anti-allergic drug [in Japanese].
        Jpn Pharmacol Ther. 1997; 25: 879-888
        • Sakamoto O
        • Okanari E
        • Ueno H
        Suppression effects of the novel drug bepotastine besilate (TAU-284) on experimental asthmatic reactions in guinea pigs [in Japanese].
        Jpn Pharmacol Ther. 1997; 25: 889-894
        • Andoh T
        • Kuraishi Y
        Suppression by bepotastine besilate of substance P-induced itch-associated responses through the inhibition of the leukotriene B4 action in mice.
        Eur J Pharmacol. 2006; 547: 59-64
        • Kaminuma O
        • Ogawa K
        • Hikkawa H
        • et al.
        A novel anti-allergic drug, betotastine besilate, suppresses interleukin-5 production by human peripheral blood mononuclear cells.
        Biol Pharm Bull. 1998; 21: 411-413
        • Ohashi Y
        Immunological study of a second-generation antihistamine — the effects of bepotastine besilate on cytokine production from the peripheral blood mononuclear cells in cedar pollen allergy patients [in Japanese].
        Prog Med. 2004; 24: 157-159
        • Narita H
        • Kikuchi M
        • Asahi T
        • et al.
        General pharmacology of betotastine besilate (TAU-284), a novel antiallergic agent [in Japanese].
        Jpn Pharmacol Ther. 1997; 25: 907-924
        • Ishibashi Y
        • Harada S
        • Niimura M
        • et al.
        Early phase II study of TAU- 284 (betotastine besilate) on chronic urticaria [in Japanese].
        J Clin Ther Med. 1997; 13: 1199-1215
        • Ishibashi Y
        • Harada S
        • Niimura M
        • et al.
        Late phase II study of TAU- 284 (betotastine besilate) on chronic urticaria—optimal dose finding study by double-blind technique [in Japanese].
        J Clin Ther Med. 1997; 13: 1237-1257
        • Ishibashi Y
        • Harada S
        • Niimura M
        • et al.
        Long term treatment of TAU- 284 (betotastine besilate) on chronic urticaria [in Japanese].
        J Clin Ther Med. 1997; 13: 1337-1359
        • Ishibashi Y
        • Harada S
        • Niimura M
        • et al.
        Clinical evaluation of TAU- 284 (betotastine besilate) on eczema/dermatitis, prurigo, and pruritus cutaneus [in Japanese].
        J Clin Ther Med. 1997; 13: 1383-1400
        • Adachi J
        Investigation of the clinical effects and safety of bepotastine besilate (Talion tablets) on patients with chronic hives [in Japanese].
        Prog Med. 2004; 24: 151-155
        • Shikanai K
        Investigation of effectiveness and safety of bepotastine besilate (Talion tablets) in cedar pollen allergy [in Japanese].
        Prog Med. 2002; 22: 2472-2477
        • Nakagawa S
        Treatment for patients with ear pruritus—investigation of antipruritic effects of bepotastine besilate [in Japanese].
        J New Rem Clin. 2003; 52: 677-681
        • Maruta H
        • Nagata M
        • Koga H
        • et al.
        Clinical evaluation of bepotastine besilate (Talion tablets) on chronic urticaria [in Japanese].
        J New Rem Clin. 2004; 53: 576-582
        • Tanaka T
        • Miyazaki S
        • Ishikawa K
        The usefulness of Talion in relation to nasal congestion in allergic rhinitis [in Japanese].
        Prog Med. 2004; 24: 2037-2044
        • Kawana S
        • Niimi Y
        • Higashi N
        • et al.
        Efficacy and safety investigation of bepotastine besilate (Talion tablets) in patients with atopic dermatitis [in Japanese].
        J New Rem Clin. 2005; 54: 1325-1331
        • Horikawa T
        • Harada S
        • Tamura S
        • et al.
        The clinical efficacy of bepotastine besilate in relation to senile dermal pruritus: Usage testing [in Japanese].
        Sci Skin. 2005; 4: 475-480
        • Ohta N
        • Akatsuka N
        • Saito F
        • et al.
        The effect of prophylactic treatment with bepotastine in patients with Japanese cedar pollinosis [in Japanese].
        Practica Otologica. 2002; 95: 531-537
        • Baba S
        • Sakakura Y
        • Iwata S
        • et al.
        Early phase II study of TAU-284 (betotastine besilate) on perennial allergic rhinitis [in Japanese].
        J Clin Ther Med. 1997; 13: 1217-1235
        • Baba S
        • Takasaki T
        • Baba K
        • et al.
        Late phase II clinical study of TAU- 284 for perennial allergic rhinitis—dose finding study by the doubleblind method [in Japanese].
        J Clin Ther Med. 1997; 13: 1259-1286
        • Koda F
        • Furue M
        Immediate clinical effectiveness of bepotastine besilate on urticaria [in Japanese].
        Nishinihon J Dermatol. 2006; 68: 544-547
        • Ito M
        • Akaogi K
        • Shimizu KA
        • et al.
        A clinical study of anti-allergy drugs in relation to allergic rhinitis [in Japanese].
        Allergol Immunol. 2003; 10: 1328-1337
        • Furue M
        • Nakahara T
        • Uranai Y
        • et al.
        The immediate effectiveness of bepotastine besilate [in Japanese].
        Jpn J Clin Exp Med. 2004; 81: 1067-1070
        • Baba S
        Post-marketing surveillance study of Talion tablets on pediatric allergic rhinitis [in Japanese].
        Rinsho Igaku. 2002; 18: 1371-1387
        • Abelson MB
        Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model.
        Ann Allergy Asthma Immunol. 1998; 81: 211-218
        • Abelson MB
        • Gomes PJ
        • Pasquine T
        • et al.
        Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis.
        Allergy Asthma Proc. 2007; 28: 427-433
        • International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
        ICH harmonized tripartite guideline. Guideline for good clinical practice E6..
        http://www.ich.org
        (Accessed June 23, 2009)
        • World Medical Association Declaration of Helsinki
        Ethical Principles for Medical Research Involving Human Subjects. 1989 Version.
        http://www.wma.net/e/policy/b3.htm
        (Accessed June 23, 2009)
        • Protzko EE
        • Williams JI
        • Gow JA
        • et al.
        The safety of the anti-histamine bepotastine besilate ophthalmic solution in a healthy pediatric population from ten to seventeen years of age.
        Invest Ophthalmol Vis Sci. 2009; 50 (E-Abstract): 6325
        • Macejko TT
        • McLaurin EB
        • Kurata FK
        • et al.
        Bepotastine besilate ophthalmic solution 1.5% reduces ocular itching following dosing in the conjunctival allergen challenge (CAC) model of acute allergic conjunctivitis.
        Invest Ophthalmol Vis Sci. 2009; 50 (E-Abstract): 6328
        • Abelson MB
        • Chambers WA
        • Smith LM
        Conjunctival allergen challenge, A clinical approach to studying allergic conjunctivitis.
        Arch Ophthalmol. 1990; 108: 84-88
        • Abelson MB
        Comparison of the conjunctival allergen challenge model with the environmental model of allergic conjunctivitis.
        Acta Ophthalmol Scand. 1999; 228: 43-46
        • Abelson MB
        • Loeffler O
        Conjunctival allergen challenge: Models in the investigation of ocular allergy.
        Curr Allergy Asthma Rep. 2003; 3: 363-368
        • Abelson MB
        • Chapin MJ
        • Kapik BM
        • Shams NB
        Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model.
        Arch Ophthalmol. 2003; 121: 626-630
      55. Bepreve (bepotastine besilate ophthalmic solution 1.5%) [package insert]. ISTA Pharmaceuticals, Inc, Irvine, Calif2009

      Article info

      Publication history

      Accepted: August 25, 2009

      Identification

      DOI: https://doi.org/10.1016/j.clinthera.2009.09.001

      Copyright

      © 2009 Excerpta Medica Inc. All rights reserved. Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX